Amicus Caritas Investor Deck FINAL

Transaction Overview - Amicus is launching Caritas Therapeutics as a next-generation genetic medicine company through a business combination with ARYA IV, a special purpose acquisition company (SPAC)[9, 19] - Caritas will launch with approximately $400 million in capital through SPAC, PIPE (Private Investment in Public Equity), and Amicus funding[4, 9, 10, 19] - Amicus will retain an approximate 36% pro forma ownership in Caritas[9, 10, 19] Leadership and Strategy - John Crowley will lead Caritas as Chairman and CEO, while remaining with Amicus as Chairman Emeritus and Chief Strategic Advisor[4, 17] - Bradley Campbell will succeed John Crowley as Amicus Chief Executive Officer upon transaction closing[4, 18] - The transaction aims to enhance the ability of both Amicus and Caritas to address unmet needs of patients with rare diseases and accelerate the development of the gene therapy portfolio[11, 19] Financial Impact - Amicus expects to become profitable as of 2023[4, 13] - Amicus is further funded through a completed $200 million private investment[4] - Two lead programs have potential $500 million - $1 billion peak sales opportunity[5, 13] Product and Pipeline - Amicus' AT-GAA NDA/BLA accepted for review with PDUFA action dates of May 29, 2022, and July 29, 2022[4] - Amicus' FY21 Revenue Guidance is $300M-$315M[6]